Glaxo says FDA has questions on restless legs drug

NEW YORK Fri Aug 10, 2007 7:35pm EDT

NEW YORK (Reuters) - U.S. regulators have concluded that GlaxoSmithKline's (GSK.L) Requip CR extended-release tablets to treat moderate-to-severe primary restless legs syndrome must meet additional conditions before getting final approval, the company said on Friday.

Glaxo said the U.S. Food and Drug Administration granted an "approvable letter" for the tablets -- a notification of conditions that must be satisfied before the regulator clears the tablets for sale.

The company said it is committed to working with the FDA to address questions it may have. Glaxo did not immediately return a call seeking comment on what those questions are.

Glaxo said the decision does not affect the current formulation of Requip tablets to treat the condition.

A couple walks along the rough surf during sunset at Oahu's North Shore, December 26, 2013. REUTERS/Kevin Lamarque

Find your dream retirement town

Florida? Hawaii? Reuters has teamed up with Zillow to give you the power to customize a list of your best places to retire.  Video | Full Article